NCT01118520View on ClinicalTrials.gov

AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Abdominal Aortic Aneurysm
Interventions
DRUG

perindopril arginine

10mgs orally daily for the duration of the trial

DRUG

amlodipine 5mgs

5 mgs taken orally daily for the duration of the trial

DRUG

placebo

one daily

Trial Locations (9)

BH7 7DW

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth

CO4 5JL

Colchester Hospital, Colchester

CV2 2DX

University Hospital Coventry and Warwickshire, Coventry

HU3 2JZ

Hull Royal Infirmary, Hull

NW3 2QG

Royal Free Hospital, London

SE1 7EH

St Thomas' Hospital, London

W21PG

St Mary's Hospital, Imperial College Healthcare NHS Trust, London

W6 8RF

Charing Cross Hospital, Imperial College NHS Trust, London

NE7 7DN

Freeman Hospital, Newcastle

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Imperial College London

OTHER

NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) | Biotech Hunter | Biotech Hunter